

SUMMARY OF ANALYSIS (SAMPLE ID: SA26333)

Testing Location: OKC 3680 E. I-240 Service Rd. Oklahoma City, OK 73135 License: LAAA-4Y4X-Z72Z	Customer ID: 724 HurryHub 1230 NW 5th St Oklahoma City, OK 73106 License: Not Entered or N/A	Order ID: OR8188 Lot Number: Not Entered Batch Number: Not Entered	Sample Type: Primary Matrix: Oil/Tincture Mass: 30g Date Collected: 04/28/2020 Date Received: 04/28/2020
--	---	---	---

Cultivar (Strain) or Sample Description: Peace River CBD Softgels **Date Completed:** 04/28/2020

*This page is simply a summary of the analysis performed. For analytical details, please consult the individual Certificate(s) of Analysis for each of the specific test(s) performed.

*For Oklahoma, with the new OMMA rules to be effective April 1, 2020, limits on moisture are proposed at 15% and water activity at 0.65aw.

Moisture Content (%) Not Tested	PASS/FAIL N/A	Water Activity (aw) Not Tested	PASS/FAIL N/A
---	-------------------------	--	-------------------------

Cannabinoids (Top 3)	(%)	mg/g
CBD	4.26	43
CBDv	0.0724	0.724
CBG	0.00725	0.0725
TOTAL CBD	4.26	43
TOTAL THC	0.00436	0.0436
TOTAL CANNABINOIDS	4.35	44

Contaminants	PASS/FAIL
Visual Inspection:	PASS



Scan the QR code to verify results.

This information is provided as a service and makes no claims of efficacy and/or safety of this product. Results are applicable only for the sample(s) analyzed and for the specific analysis conducted. This report is for informational purposes only and should not be used to diagnose, treat, or prevent any medical-related symptoms. The statements and results herein have not been approved and/or endorsed by the FDA.

REPORT OF LABORATORY ANALYSIS

This report shall not be reproduced, except in full, without the written consent of Felling Analytical Services and Technology of Oklahoma City, LLC

Kyle W. Felling
Kyle W. Felling, Ph.D.
Laboratory Director



CERTIFICATE OF ANALYSIS (SAMPLE ID: SA26333)

Testing Location: OKC 3680 E. I-240 Service Rd. Oklahoma City, OK 73135 License: LAAA-4Y4X-Z72Z	Customer ID: 724 HurryHub 1230 NW 5th St Oklahoma City, OK 73106 License: Not Entered or N/A	Order ID: OR8188 Lot Number: Not Entered Batch Number: Not Entered	Sample Type: Primary Matrix: Oil/Tincture Mass: 30g Date Collected: 04/28/2020 Date Received: 04/28/2020
--	---	---	---

Cultivar (Strain) or Sample Description: Peace River CBD Softgels **Date Completed:** 04/28/2020

CANNABINOID (POTENCY) PROFILE

Analysis Date/Time: 04/28/2020 1043
Analyst: WW

Method: HPLC/DAD
Instrument: Agilent 1100

Moisture Content (%): -
Water Activity (aw): -

<u>Cannabinoid</u>	<u>Result (%)</u>	<u>Result (mg/g)</u>	<u>Reporting Limit (mg/g)</u>	<u>Result (mg/mL)</u>	<u>Per Unit (mg)</u>
CBD	4.26	42.6	0.025	-	25
CBDa	-	-	0.025	-	-
CBDv	0.0724	0.724	0.025	-	0.429
Δ9-THC	0.00436	0.0436	0.025	-	0.0259
Δ8-THC	0.00487	0.0487	0.025	-	0.0289
THCa	-	-	0.025	-	-
THCv	-	-	0.025	-	-
CBC	-	-	0.025	-	-
CBG	0.00725	0.0725	0.025	-	0.043
CBGa	-	-	0.025	-	-
CBN	-	-	0.025	-	-
TOTAL	4.35	44		-	26
TOTAL THC	0.00436	0.0436		-	0.0259
TOTAL CBD	4.26	43		-	25




UNIT MASS (g): 0.59318

"-" Not detected above RL.

Cannabinoid Distribution

(% of Total Cannabinoids)



Deviations from standard operating procedure: None

Recoveries for all analyte standards: 90-110%
Replicate Uncertainties: <5% RSD, <20% RPD
Sample/Reagent Blanks: <RL for all analytes

Values for plant matter are adjusted for moisture content.

Total THC = (THCa x 0.877) + Δ9-THC
Total CBD = (CBDa x 0.877) + CBD

Percentage results are reported by mass.
mg/g results are reported as mass component per mass material.

Abbreviations: UV - Ultraviolet, HPLC - High Pressure Liquid Chromatography, RL - Reporting Limit, RPD - Relative Percent Difference, RSD - Relative Standard Deviation

This information is provided as a service and makes no claims of efficacy and/or safety of this product. Results are applicable only for the sample(s) analyzed and for the specific analysis conducted. This report is for informational purposes only and should not be used to diagnose, treat, or prevent any medical-related symptoms. The statements and results herein have not been approved and/or endorsed by the FDA.

REPORT OF LABORATORY ANALYSIS

This report shall not be reproduced, except in full, without the written consent of Felling Analytical Services and Technology of Oklahoma City, LLC

Kyle W. Felling
Kyle W. Felling, Ph.D.
Laboratory Director

